Please login to the form below

Not currently logged in
Email:
Password:

Hunter syndrome

This page shows the latest Hunter syndrome news and features for those working in and with pharma, biotech and healthcare.

Sangamo’s first gene-editing trial doesn’t convince investors

Sangamo’s first gene-editing trial doesn’t convince investors

Market spooked by inconclusive early results. Sangamo Therapeutics has claimed a first with a trial of its genome-editing technology for rare disease Hunter syndrome, but the data didn’t convince ... gene-editing technology that is designed to modify

Latest news

More from news
Approximately 3 fully matching, plus 22 partially matching documents found.

Latest Intelligence

  • Deal Watch table for July 2014 Deal Watch table for July 2014

    360. Sigma-Tau/ Jazz Pharmaceuticals. Regaining rights. Defibrotide for severe hepatic veno-occlusive disease (approved EU/ NDA US)    . 250. ArmaGen/ Shire   . Licence, collaboration   . AGT-182, enzyme replacement therapy for Hunter

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 0 fully matching, plus 2 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Fendix

Latest intelligence

Unlocking the potential of science and technology in the UK
Greater collaboration is vital in post-Brexit UK, says Alderley Park leader...
NHS regional footprints
What to expect from 2019...
Not another weight-loss ad
Christmas is over and the gyms are packed, it’s a never-ending tale. But why do we do it to ourselves every year?...

Infographics